Abstract
Colorectal carcinoma is a heterogenous disease. Advancements in molecular biology of tumors lead to definition of specific subtypes.
For many of them targeted therapy known as personalized (precision) treatment is available. dMMR/MSI-H CRC is one of these subtypes, where immunotherapy leads to significant and long lasting response. This review summarizes current options in treatment of dMMR/MSI-H CRC.